Wedbush expects visibility in 2019 into Del Taco's (TACO) long-term MSD-HSD EBITDA growth algorithm to result in valuation expansion toward its regional Restaurant Brands (QSR) peers, and is adding the stock to its Best Ideas List. Reiterating an Overweight rating on the shares and also adding it to its Best Ideas List, Wedbush says ObsEva (OBSV) continues to deliver stellar clinical results from its drug candidate pipeline. The firm anticipates Linzagolix to be the third entrant in the oral gonadotropin releasing hormone receptor antagonist space, but its differentiated profile and dosing options are likely to be preferred by patients.